Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 13 studies | 25% ± 9% | |
lung | 10 studies | 28% ± 12% | |
kidney | 6 studies | 20% ± 4% | |
intestine | 6 studies | 23% ± 12% | |
eye | 5 studies | 33% ± 11% | |
brain | 5 studies | 31% ± 15% | |
lymph node | 4 studies | 25% ± 8% | |
pancreas | 3 studies | 35% ± 20% | |
uterus | 3 studies | 29% ± 14% | |
liver | 3 studies | 35% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 7041.36 | 2642 / 2642 | 100% | 56.15 | 705 / 705 |
esophagus | 100% | 3045.97 | 1445 / 1445 | 100% | 23.01 | 183 / 183 |
ovary | 100% | 2460.98 | 180 / 180 | 100% | 41.34 | 430 / 430 |
uterus | 100% | 2730.65 | 170 / 170 | 100% | 38.91 | 459 / 459 |
liver | 100% | 1486.93 | 226 / 226 | 100% | 22.54 | 405 / 406 |
kidney | 100% | 2755.02 | 89 / 89 | 100% | 26.88 | 898 / 901 |
prostate | 100% | 3537.80 | 245 / 245 | 100% | 52.86 | 500 / 502 |
adrenal gland | 100% | 3691.75 | 258 / 258 | 100% | 53.20 | 229 / 230 |
thymus | 100% | 2265.36 | 651 / 653 | 100% | 34.51 | 604 / 605 |
skin | 100% | 2257.28 | 1807 / 1809 | 100% | 40.26 | 470 / 472 |
intestine | 100% | 3047.43 | 966 / 966 | 99% | 27.39 | 524 / 527 |
stomach | 100% | 2217.06 | 359 / 359 | 99% | 26.68 | 284 / 286 |
lung | 99% | 2369.81 | 575 / 578 | 99% | 25.51 | 1146 / 1155 |
bladder | 100% | 3036.29 | 21 / 21 | 99% | 31.62 | 497 / 504 |
breast | 100% | 2378.41 | 459 / 459 | 98% | 27.49 | 1101 / 1118 |
pancreas | 94% | 1092.44 | 308 / 328 | 100% | 31.11 | 178 / 178 |
eye | 0% | 0 | 0 / 0 | 100% | 35.89 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 53.50 | 29 / 29 |
spleen | 100% | 2734.78 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 38.50 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.68 | 1 / 1 |
blood vessel | 100% | 3098.01 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 2433.84 | 1202 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 2366.55 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2798.56 | 849 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 1903.67 | 877 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042177 | Biological process | negative regulation of protein catabolic process |
GO_0010468 | Biological process | regulation of gene expression |
GO_0060392 | Biological process | negative regulation of SMAD protein signal transduction |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0043547 | Biological process | positive regulation of GTPase activity |
GO_0035307 | Biological process | positive regulation of protein dephosphorylation |
GO_0090263 | Biological process | positive regulation of canonical Wnt signaling pathway |
GO_0032092 | Biological process | positive regulation of protein binding |
GO_1902430 | Biological process | negative regulation of amyloid-beta formation |
GO_0070373 | Biological process | negative regulation of ERK1 and ERK2 cascade |
GO_0001932 | Biological process | regulation of protein phosphorylation |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0032465 | Biological process | regulation of cytokinesis |
GO_0030182 | Biological process | neuron differentiation |
GO_0046785 | Biological process | microtubule polymerization |
GO_0050821 | Biological process | protein stabilization |
GO_0001666 | Biological process | response to hypoxia |
GO_1900180 | Biological process | regulation of protein localization to nucleus |
GO_0032091 | Biological process | negative regulation of protein binding |
GO_0050808 | Biological process | synapse organization |
GO_2000146 | Biological process | negative regulation of cell motility |
GO_0031647 | Biological process | regulation of protein stability |
GO_0000413 | Biological process | protein peptidyl-prolyl isomerization |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0007088 | Biological process | regulation of mitotic nuclear division |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0030496 | Cellular component | midbody |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0099524 | Cellular component | postsynaptic cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0036064 | Cellular component | ciliary basal body |
GO_0005634 | Cellular component | nucleus |
GO_0031434 | Molecular function | mitogen-activated protein kinase kinase binding |
GO_0032794 | Molecular function | GTPase activating protein binding |
GO_0003755 | Molecular function | peptidyl-prolyl cis-trans isomerase activity |
GO_0008013 | Molecular function | beta-catenin binding |
GO_0016859 | Molecular function | cis-trans isomerase activity |
GO_0003774 | Molecular function | cytoskeletal motor activity |
GO_0050816 | Molecular function | phosphothreonine residue binding |
GO_0048156 | Molecular function | tau protein binding |
GO_1990757 | Molecular function | ubiquitin ligase activator activity |
GO_0051219 | Molecular function | phosphoprotein binding |
GO_0050815 | Molecular function | phosphoserine residue binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PIN1 |
Protein name | Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (EC 5.2.1.8) (Peptidyl-prolyl cis-trans isomerase Pin1) (PPIase Pin1) (Rotamase Pin1) Prolyl isomerase Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
Synonyms | |
Description | FUNCTION: Peptidyl-prolyl cis/trans isomerase (PPIase) that binds to and isomerizes specific phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs . By inducing conformational changes in a subset of phosphorylated proteins, acts as a molecular switch in multiple cellular processes . Displays a preference for acidic residues located N-terminally to the proline bond to be isomerized. Regulates mitosis presumably by interacting with NIMA and attenuating its mitosis-promoting activity. Down-regulates kinase activity of BTK . Can transactivate multiple oncogenes and induce centrosome amplification, chromosome instability and cell transformation. Required for the efficient dephosphorylation and recycling of RAF1 after mitogen activation . Binds and targets PML and BCL6 for degradation in a phosphorylation-dependent manner . Acts as a regulator of JNK cascade by binding to phosphorylated FBXW7, disrupting FBXW7 dimerization and promoting FBXW7 autoubiquitination and degradation: degradation of FBXW7 leads to subsequent stabilization of JUN . May facilitate the ubiquitination and proteasomal degradation of RBBP8/CtIP through CUL3/KLHL15 E3 ubiquitin-protein ligase complex, hence favors DNA double-strand repair through error-prone non-homologous end joining (NHEJ) over error-free, RBBP8-mediated homologous recombination (HR) . Upon IL33-induced lung inflammation, catalyzes cis-trans isomerization of phosphorylated IRAK3/IRAK-M, inducing IRAK3 stabilization, nuclear translocation and expression of pro-inflammatory genes in dendritic cells . . |
Accessions | K7EP26 Q13526 Q49AR7 ENST00000587625.5 Q8NFL2 ENST00000591777.1 K7EMU7 ENST00000586352.5 ENST00000247970.9 ENST00000588695.5 K7EN45 |